199 related articles for article (PubMed ID: 30580105)
21. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
[TBL] [Abstract][Full Text] [Related]
22. [Retrospective analysis of hemotherapy support in 226 cases of myelodysplastic syndromes].
Rubio-Félix D; Franco E; Giraldo P; Gimeno J; Cuesta I; Giralt M
Sangre (Barc); 1994 Apr; 39(2):117-20. PubMed ID: 8059289
[TBL] [Abstract][Full Text] [Related]
23. An audit of platelet transfusion within the Wellington Cancer Centre.
Buhrkuhl DC; Karlsson MK; Carter JM
Intern Med J; 2012 Jan; 42(1):65-70. PubMed ID: 21040321
[TBL] [Abstract][Full Text] [Related]
24. Successful use of rituximab in platelet transfusion refractoriness in a multi-transfused patient with myelodysplastic syndrome.
Yu QH; Shen YP; Ye BD; Zhou YH
Platelets; 2015; 26(2):195-6. PubMed ID: 23634876
[TBL] [Abstract][Full Text] [Related]
25. Randomized Trial of Platelet-Transfusion Thresholds in Neonates.
Curley A; Stanworth SJ; Willoughby K; Fustolo-Gunnink SF; Venkatesh V; Hudson C; Deary A; Hodge R; Hopkins V; Lopez Santamaria B; Mora A; Llewelyn C; D'Amore A; Khan R; Onland W; Lopriore E; Fijnvandraat K; New H; Clarke P; Watts T;
N Engl J Med; 2019 Jan; 380(3):242-251. PubMed ID: 30387697
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study.
Wandt H; Schaefer-Eckart K; Wendelin K; Pilz B; Wilhelm M; Thalheimer M; Mahlknecht U; Ho A; Schaich M; Kramer M; Kaufmann M; Leimer L; Schwerdtfeger R; Conradi R; Dölken G; Klenner A; Hänel M; Herbst R; Junghanss C; Ehninger G;
Lancet; 2012 Oct; 380(9850):1309-16. PubMed ID: 22877506
[TBL] [Abstract][Full Text] [Related]
27. Lobectomy for lung cancer in a myelodysplastic syndrome patient with decreasing platelet aggregation: report of a case.
Koezuka S; Hata Y; Otsuka H; Makino T; Azuma Y; Azumi T; Anami Y; Natori K; Iyoda A
J Cardiothorac Surg; 2018 Jul; 13(1):89. PubMed ID: 30041670
[TBL] [Abstract][Full Text] [Related]
28. [Myelodysplastic syndrome with refractory hemorrhage due to reduced platelet aggregation activity].
Tanaka T; Kozakai T; Kitajima T; Fuse K; Kobayashi H; Ushiki T; Shibazaki Y; Moriyama M; Takizawa J; Sone H; Fuse I; Masuko M
Rinsho Ketsueki; 2017; 58(12):2402-2405. PubMed ID: 29332874
[TBL] [Abstract][Full Text] [Related]
29. Safety and cost effectiveness of a 10 x 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 x 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia.
Wandt H; Frank M; Ehninger G; Schneider C; Brack N; Daoud A; Fackler-Schwalbe I; Fischer J; Gäckle R; Geer T; Harms P; Löffler B; Ohl S; Otremba B; Raab M; Schönrock-Nabulsi P; Strobel G; Winter R; Link H
Blood; 1998 May; 91(10):3601-6. PubMed ID: 9572994
[TBL] [Abstract][Full Text] [Related]
30. International Study of the Epidemiology of Platelet Transfusions in Critically Ill Children With an Underlying Oncologic Diagnosis.
Nellis ME; Goel R; Karam O; Cushing MM; Davis PJ; Steiner ME; Tucci M; Stanworth SJ; Spinella PC;
Pediatr Crit Care Med; 2019 Jul; 20(7):e342-e351. PubMed ID: 31107379
[TBL] [Abstract][Full Text] [Related]
31. Influence of platelet count at diagnosis and during the course of disease on prognosis in MDS patients.
Strapatsas J; Barbulescu EC; Lauseker M; Kaivers J; Hildebrandt B; Nachtkamp K; Strupp C; Rudelius M; Haas R; Germing U
Ann Hematol; 2021 Oct; 100(10):2575-2584. PubMed ID: 34324021
[TBL] [Abstract][Full Text] [Related]
32. Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies.
Antun AG; Gleason S; Arellano M; Langston AA; McLemore ML; Gaddh M; el Rassi F; Bernal-Mizrachi L; Galipeau J; Heffner LT; Winton EF; Khoury HJ
Cancer; 2013 Nov; 119(21):3784-7. PubMed ID: 23921838
[TBL] [Abstract][Full Text] [Related]
33. The burden of immune-mediated refractoriness to platelet transfusions in myelodysplastic syndromes.
Cheok KPL; Chhetri R; Wee LYA; Friel O; Pham A; Salvi A; McRae S; Bardy P; Singhal D; Roxby DJ; Wood EM; Hiwase DK
Transfusion; 2020 Oct; 60(10):2192-2198. PubMed ID: 32905635
[TBL] [Abstract][Full Text] [Related]
34. Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim.
Krečak I; Skorić I; Čengić M; Krečak F; Skelin M
Transfus Apher Sci; 2023 Apr; 62(2):103582. PubMed ID: 36253251
[TBL] [Abstract][Full Text] [Related]
35. Feasibility and usefulness of self-assessment of bleeding in patients with haematological malignancies, and the association between platelet count and bleeding.
Stanworth SJ; Dyer C; Casbard A; Murphy MF
Vox Sang; 2006 Jul; 91(1):63-9. PubMed ID: 16756603
[TBL] [Abstract][Full Text] [Related]
36. Effects of platelet and plasma transfusion on outcome in traumatic brain injury patients with moderate bleeding diatheses.
Anglin CO; Spence JS; Warner MA; Paliotta C; Harper C; Moore C; Sarode R; Madden C; Diaz-Arrastia R
J Neurosurg; 2013 Mar; 118(3):676-86. PubMed ID: 23259827
[TBL] [Abstract][Full Text] [Related]
37. Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome.
Strauss R; Wehler M; Mehler K; Kreutzer D; Koebnick C; Hahn EG
Crit Care Med; 2002 Aug; 30(8):1765-71. PubMed ID: 12163790
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Significance of Platelet Recovery in Myelodysplastic Syndromes With Severe Thrombocytopenia.
Tang Y; Zhang X; Han S; Chu T; Qi J; Wang H; Tang X; Qiu H; Fu C; Ruan C; Wu D; Han Y
Clin Appl Thromb Hemost; 2018 Dec; 24(9_suppl):217S-222S. PubMed ID: 30296835
[TBL] [Abstract][Full Text] [Related]
39. Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS).
Oliva EN; Riva M; Niscola P; Santini V; Breccia M; Giai V; Poloni A; Patriarca A; Crisà E; Capodanno I; Salutari P; Reda G; Cascavilla N; Ferrero D; Guarini A; Tripepi G; Iannì G; Russo E; Castelli A; Fattizzo B; Beltrami G; Bocchia M; Molteni A; Fenaux P; Germing U; Ricco A; Palumbo GA; Impera S; Di Renzo N; Rivellini F; Buccisano F; Stamatoullas-Bastard A; Liberati AM; Candoni A; Delfino IM; Arcadi MT; Cufari P; Rizzo L; Bova I; D'Errigo MG; Zini G; Latagliata R
J Clin Oncol; 2023 Oct; 41(28):4486-4496. PubMed ID: 37294914
[TBL] [Abstract][Full Text] [Related]
40. Prophylactic platelet transfusion plus supportive care versus supportive care alone in adults with dengue and thrombocytopenia: a multicentre, open-label, randomised, superiority trial.
Lye DC; Archuleta S; Syed-Omar SF; Low JG; Oh HM; Wei Y; Fisher D; Ponnampalavanar SSL; Wijaya L; Lee LK; Ooi EE; Kamarulzaman A; Lum LC; Tambyah PA; Leo YS
Lancet; 2017 Apr; 389(10079):1611-1618. PubMed ID: 28283286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
